Firefly Neuroscience Inc. Financials
Firefly Neuroscience Inc. (AIFF) reported $1.1M in revenue for fiscal year 2025, up 957.4% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing is doing the heavy lifting while cash burn still outweighs this business's early and still-thin commercial output.
By FY2025, after the FY2024 squeeze, liquidity improved enough for the current ratio to reach 1.4x and for reported equity to turn positive again. But the repair came from outside the business, because financing inflow of$11.6M more than covered operating cash outflow of-$8.2M .
The revenue rebound to
FY2025 net loss of
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Firefly Neuroscience Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Firefly Neuroscience Inc. scores -13.88, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($16.9M) relative to total liabilities ($2.8M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Firefly Neuroscience Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Firefly Neuroscience Inc. reported a net loss of $19.9M while operations used $8.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Firefly Neuroscience Inc. generated $1.1M in revenue in fiscal year 2025. This represents an increase of 957.4% from the prior year.
Firefly Neuroscience Inc.'s EBITDA was -$8.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.0% from the prior year.
Firefly Neuroscience Inc. reported -$19.9M in net income in fiscal year 2025. This represents a decrease of 90.1% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Firefly Neuroscience Inc. held $2.7M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Firefly Neuroscience Inc.'s gross margin was 56.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 43.5 percentage points from the prior year.
Firefly Neuroscience Inc.'s ROE was -260.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Firefly Neuroscience Inc. invested $1.5M in research and development in fiscal year 2025. This represents a decrease of 24.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
AIFF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8M | $1.1M+957.4% | $108K-78.3% | $498K-95.9% | $12.0M-20.0% | $15.0M+8.1% | $13.9M+36.8% | $10.2M+13.8% | $8.9M-16.0% | $10.6M+58.1% | $6.7M+8.3% | $6.2M+7.5% | $5.8M-22.7% | $7.5M+6.0% | $7.1M-9.8% | $7.8M |
| Cost of Revenue | $997K | $497K | $0-100.0% | $5.4M-34.2% | $8.2M-28.5% | $11.4M-2.4% | $11.7M+33.4% | $8.8M+29.1% | $6.8M-17.4% | $8.2M+67.7% | $4.9M+27.7% | $3.8M+13.1% | $3.4M-34.9% | $5.2M+12.3% | $4.6M-13.6% | $5.4M |
| Gross Profit | $802K | $645K+497.2% | $108K+102.2% | -$4.9M-270.1% | $2.9M-20.8% | $3.6M+63.7% | $2.2M+57.8% | $1.4M-34.7% | $2.1M-11.3% | $2.4M+32.5% | $1.8M-23.2% | $2.4M-0.6% | $2.4M+5.7% | $2.3M-6.3% | $2.4M-1.3% | $2.4M |
| R&D Expenses | $1.8M | $1.5M-24.2% | $2.0M+163.7% | $741K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $7.2M | $7.0M+13.6% | $6.1M+5.0% | $5.8M-29.5% | $8.3M+32.7% | $6.2M+247.3% | $1.8M-4.1% | $1.9M+7.4% | $1.7M+4.3% | $1.7M-10.9% | $1.9M+7.5% | $1.7M+3.6% | $1.7M+2.0% | $1.7M-1.8% | $1.7M+7.7% | $1.6M |
| Operating Income | -$9.1M | -$8.9M+11.9% | -$10.1M-226.6% | -$3.1M+43.2% | -$5.4M-106.3% | -$2.6M-737.9% | $412K+156.6% | -$728K-1067.4% | -$62K-126.2% | $238K+142.2% | -$563K-927.1% | $68K+271.0% | -$40K+42.5% | -$69K-173.5% | $94K-36.7% | $149K |
| Interest Expense | N/A | N/A | N/A | $103K+26.5% | $82K+118.7% | $37K+1094.4% | $3K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $5K+350.0% | -$2K-300.0% | $1K-99.9% | $812K+175.9% | -$1.1M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$9.1M | -$19.9M-90.1% | -$10.5M-301.8% | -$2.6M+85.3% | -$17.8M-1469.1% | -$1.1M-373.7% | $413K+157.6% | -$717K-1305.4% | -$51K-120.7% | $246K+144.5% | -$554K-806.9% | $78K+363.0% | -$30K+50.6% | -$60K-160.0% | $100K-34.5% | $153K |
| EPS (Diluted) | — | N/A | N/A | N/A | N/A | -$0.09-400.0% | $0.03+150.0% | -$0.06 | $0.00-100.0% | $0.02+140.0% | -$0.05-600.0% | $0.01 | $0.00+100.0% | -$0.01 | $0.01 | $0.01 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AIFF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $10.5M+127.7% | $4.6M+74.2% | $2.6M-66.9% | $8.0M-65.8% | $23.4M+519.1% | $3.8M+59.0% | $2.4M-21.5% | $3.0M-19.0% | $3.7M-0.5% | $3.8M-8.9% | $4.1M-3.1% | $4.2M-3.6% | $4.4M+22.3% | $3.6M-28.1% | $5.0M |
| Current Assets | $4.0M+53.2% | $2.6M+16.5% | $2.3M-19.6% | $2.8M-59.2% | $6.9M+99.6% | $3.4M+55.9% | $2.2M-26.6% | $3.0M-19.0% | $3.7M0.0% | $3.7M-8.6% | $4.1M-2.8% | $4.2M-3.6% | $4.3M+22.0% | $3.6M-28.4% | $5.0M |
| Cash & Equivalents | $2.7M+51.8% | $1.8M+165.4% | $682K-6.7% | $731K-85.2% | $4.9M+165.4% | $1.9M+78.8% | $1.0M-47.1% | $2.0M-28.1% | $2.7M+44.1% | $1.9M-12.6% | $2.2M-11.5% | $2.5M+3.8% | $2.4M-10.0% | $2.6M+104.8% | $1.3M |
| Inventory | $108K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $194K+60.3% | $121K+44.0% | $84K-94.8% | $1.6M-2.1% | $1.7M+15.4% | $1.4M+115.7% | $669K+2.4% | $653K+7.0% | $610K-47.3% | $1.2M-10.8% | $1.3M+33.7% | $971K-32.5% | $1.4M+94.8% | $738K-74.5% | $2.9M |
| Goodwill | $5.2M | $0 | $0-100.0% | $1.1M-85.2% | $7.6M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $2.8M-42.9% | $5.0M+96.5% | $2.5M-75.2% | $10.2M+72.4% | $5.9M+174.1% | $2.2M+78.3% | $1.2M+5.3% | $1.2M-37.5% | $1.8M-13.2% | $2.1M+9.2% | $1.9M-10.1% | $2.2M-6.1% | $2.3M+58.0% | $1.5M-51.1% | $3.0M |
| Current Liabilities | $2.8M-43.3% | $5.0M+96.5% | $2.5M-34.9% | $3.9M+96.2% | $2.0M+9.9% | $1.8M+54.6% | $1.2M+1.3% | $1.2M-37.5% | $1.8M-13.2% | $2.1M+9.2% | $1.9M-10.1% | $2.2M-6.1% | $2.3M+58.0% | $1.5M-51.1% | $3.0M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $357K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.6M+2136.5% | -$375K-444.0% | $109K+104.9% | -$2.2M-112.8% | $17.4M+981.0% | $1.6M+38.8% | $1.2M-37.9% | $1.9M-1.1% | $1.9M+16.0% | $1.6M-25.0% | $2.2M+4.2% | $2.1M-0.7% | $2.1M-2.0% | $2.1M+5.3% | $2.0M |
| Retained Earnings | -$111.6M-28.2% | -$87.1M-13.7% | -$76.6M-145.7% | -$31.2M-132.1% | -$13.4M-9.2% | -$12.3M+3.3% | -$12.7M-6.0% | -$12.0M-0.4% | -$12.0M+2.0% | -$12.2M-4.8% | -$11.6M+0.7% | -$11.7M-0.3% | -$11.7M-0.5% | -$11.6M+0.9% | -$11.7M |
AIFF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.0M | -$8.2M-33.1% | -$6.2M-183.4% | -$2.2M+63.9% | -$6.0M-718.2% | -$735K-273.7% | $423K+146.2% | -$917K-20.1% | -$764K-191.3% | $836K+425.9% | -$257K+3.2% | -$265K-327.1% | $117K+154.1% | -$216K-115.8% | $1.4M+303.7% | -$669K |
| Capital Expenditures | N/A | N/A | N/A | $0-100.0% | $536K+668.3% | $70K+8.1% | $65K+671.4% | $8K+45.0% | $6K+587.0% | $840-93.7% | $13K-26.4% | $18K-43.3% | $32K-17.9% | $39K+49.2% | $26K+8.5% | $24K |
| Free Cash Flow | N/A | N/A | N/A | -$2.2M+66.8% | -$6.5M-713.9% | -$805K-324.3% | $359K+138.8% | -$926K-20.3% | -$769K-192.1% | $835K+409.4% | -$270K+4.7% | -$283K-435.1% | $85K+133.2% | -$255K-119.1% | $1.3M+292.8% | -$694K |
| Investing Cash Flow | -$209K | -$2.5M-421.6% | -$477K-23.6% | -$386K+28.0% | -$536K+94.4% | -$9.6M-14745.3% | -$65K-671.4% | -$8K-106.5% | -$4K-5807.0% | $71+100.4% | -$16K+6.1% | -$17K+34.8% | -$26K+45.2% | -$48K-121.5% | -$22K-21.6% | -$18K |
| Financing Cash Flow | $10.5M | $11.6M+84.5% | $6.3M+35.7% | $4.6M+97.6% | $2.3M-82.5% | $13.4M+2810.9% | $460K+45900.0% | $1K | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $350-94.6% | $6K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
AIFF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.5%-43.5pp | 100.0% | -977.8% | 23.8%-0.2pp | 24.1%+8.2pp | 15.9%+2.1pp | 13.8%-10.2pp | 24.0%+1.3pp | 22.7%-4.4pp | 27.1%-11.1pp | 38.2%-3.1pp | 41.3%+11.1pp | 30.2%-4.0pp | 34.2%+2.9pp | 31.2% |
| Operating Margin | -775.5% | -9309.3% | -618.1% | -45.1%-27.6pp | -17.5%-20.4pp | 3.0%+10.1pp | -7.2%-6.5pp | -0.7%-2.9pp | 2.2%+10.6pp | -8.4%-9.5pp | 1.1%+1.8pp | -0.7%+0.2pp | -0.9%-2.3pp | 1.3%-0.6pp | 1.9% |
| Net Margin | -1741.0% | -9685.2% | -522.7% | -147.7% | -7.5%-10.5pp | 3.0%+10.0pp | -7.1%-6.5pp | -0.6%-2.9pp | 2.3%+10.5pp | -8.2%-9.5pp | 1.3%+1.8pp | -0.5%+0.3pp | -0.8%-2.2pp | 1.4%-0.5pp | 2.0% |
| Return on Equity | -260.3% | N/A | -2388.1% | N/A | -6.5%-32.1pp | 25.6%+87.3pp | -61.7%-59.0pp | -2.7%-15.7pp | 13.0%+46.9pp | -33.9%-37.5pp | 3.6%+5.0pp | -1.4%+1.4pp | -2.9%-7.5pp | 4.7%-2.8pp | 7.5% |
| Return on Assets | -189.8%+37.6pp | -227.3%-128.8pp | -98.6%+123.9pp | -222.4%-217.6pp | -4.8%-15.8pp | 10.9%+41.2pp | -30.2%-28.5pp | -1.7%-8.3pp | 6.6%+21.4pp | -14.8%-16.7pp | 1.9%+2.6pp | -0.7%+0.7pp | -1.4%-4.2pp | 2.8%-0.3pp | 3.1% |
| Current Ratio | 1.43+0.9x | 0.53-0.4x | 0.89+0.2x | 0.72-2.7x | 3.47+1.6x | 1.910.0x | 1.89-0.7x | 2.62+0.6x | 2.02+0.3x | 1.75-0.3x | 2.10+0.2x | 1.94+0.1x | 1.89-0.6x | 2.44+0.8x | 1.67 |
| Debt-to-Equity | 0.37 | N/A | 23.23 | N/A | 0.34+0.1x | 0.22-0.8x | 1.04+0.4x | 0.61-0.4x | 0.97-0.3x | 1.30+0.4x | 0.89-0.1x | 1.03-0.1x | 1.09+0.4x | 0.68-0.8x | 1.46 |
| FCF Margin | N/A | N/A | -436.1% | -54.5%-49.1pp | -5.3%-7.9pp | 2.6%+11.7pp | -9.1%-0.5pp | -8.6%-16.5pp | 7.8%+11.9pp | -4.0%+0.6pp | -4.6%-6.0pp | 1.5%+4.9pp | -3.4%-22.4pp | 18.9%+27.8pp | -8.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Firefly Neuroscience Inc. Ranks
Frequently Asked Questions
What is Firefly Neuroscience Inc.'s annual revenue?
Firefly Neuroscience Inc. (AIFF) reported $1.1M in total revenue for fiscal year 2025. This represents a 957.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Firefly Neuroscience Inc.'s revenue growing?
Firefly Neuroscience Inc. (AIFF) revenue grew by 957.4% year-over-year, from $108K to $1.1M in fiscal year 2025.
Is Firefly Neuroscience Inc. profitable?
No, Firefly Neuroscience Inc. (AIFF) reported a net income of -$19.9M in fiscal year 2025.
What is Firefly Neuroscience Inc.'s EBITDA?
Firefly Neuroscience Inc. (AIFF) had EBITDA of -$8.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Firefly Neuroscience Inc.'s gross margin?
Firefly Neuroscience Inc. (AIFF) had a gross margin of 56.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Firefly Neuroscience Inc.'s return on equity (ROE)?
Firefly Neuroscience Inc. (AIFF) has a return on equity of -260.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Firefly Neuroscience Inc.'s operating cash flow?
Firefly Neuroscience Inc. (AIFF) recorded an outflow of $8.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Firefly Neuroscience Inc.'s total assets?
Firefly Neuroscience Inc. (AIFF) had $10.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Firefly Neuroscience Inc. spend on research and development?
Firefly Neuroscience Inc. (AIFF) invested $1.5M in research and development during fiscal year 2025.
What is Firefly Neuroscience Inc.'s current ratio?
Firefly Neuroscience Inc. (AIFF) had a current ratio of 1.43 as of fiscal year 2025, which is considered adequate.
What is Firefly Neuroscience Inc.'s debt-to-equity ratio?
Firefly Neuroscience Inc. (AIFF) had a debt-to-equity ratio of 0.37 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Firefly Neuroscience Inc.'s return on assets (ROA)?
Firefly Neuroscience Inc. (AIFF) had a return on assets of -189.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Firefly Neuroscience Inc.'s cash runway?
Based on fiscal year 2025 data, Firefly Neuroscience Inc. (AIFF) had $2.7M in cash against an annual operating cash burn of $8.2M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Firefly Neuroscience Inc.'s Altman Z-Score?
Firefly Neuroscience Inc. (AIFF) has an Altman Z-Score of -13.88, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Firefly Neuroscience Inc.'s Piotroski F-Score?
Firefly Neuroscience Inc. (AIFF) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Firefly Neuroscience Inc.'s earnings high quality?
Firefly Neuroscience Inc. (AIFF) reported a net loss of $19.9M while operations used $8.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Firefly Neuroscience Inc.?
Firefly Neuroscience Inc. (AIFF) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.